Allogeneic hematopoietic stem cell transplantation (HSCT) is widely performed in children and adolescents with hematologic diseases, including very high-risk leukemia. With increasing success and survival rates, the long-term sequelae of HSCT have become important. Here, we provide guidance to the prevention and treatment of the most common bone morbidities—osteoporosis and osteonecrosis—emerging in the context of HSCT in children and adolescents. We give an overview on definitions, symptoms, and diagnostics and propose an algorithm for clinical practice based on discussions within the International Berlin Frankfurt Münster (BFM) Stem Cell Transplantation Committee and the Pediatric Disease Working Party of the European Society for Blood and Marrow Transplantation, our expert knowledge, and a literature review

Kuhlen, M., Kunstreich, M., Niinimaki, R., Dunstheimer, D., Lawitschka, A., Bardi, E., et al. (2020). Guidance to Bone Morbidity in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Bone Morbidity in Children after HSCT. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 26(2), e27-e37 [10.1016/j.bbmt.2019.10.007].

Guidance to Bone Morbidity in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Bone Morbidity in Children after HSCT

Balduzzi A.
Ultimo
Membro del Collaboration Group
2020

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is widely performed in children and adolescents with hematologic diseases, including very high-risk leukemia. With increasing success and survival rates, the long-term sequelae of HSCT have become important. Here, we provide guidance to the prevention and treatment of the most common bone morbidities—osteoporosis and osteonecrosis—emerging in the context of HSCT in children and adolescents. We give an overview on definitions, symptoms, and diagnostics and propose an algorithm for clinical practice based on discussions within the International Berlin Frankfurt Münster (BFM) Stem Cell Transplantation Committee and the Pediatric Disease Working Party of the European Society for Blood and Marrow Transplantation, our expert knowledge, and a literature review
Articolo in rivista - Articolo scientifico
Allogeneic HSCT; Bone morbidity; Children and adolescents; Leukemia
English
2020
26
2
e27
e37
none
Kuhlen, M., Kunstreich, M., Niinimaki, R., Dunstheimer, D., Lawitschka, A., Bardi, E., et al. (2020). Guidance to Bone Morbidity in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Bone Morbidity in Children after HSCT. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 26(2), e27-e37 [10.1016/j.bbmt.2019.10.007].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/260932
Citazioni
  • Scopus 8
  • ???jsp.display-item.citation.isi??? ND
Social impact